8 research outputs found
Helicometrina nimia Linton, 1910 (Digenea: Opecoelidae) in dusky grouper Epinephelus marginatus (Lowe, 1834) (Teleostei: Serranidae) from southeastern Brazil
In-depth proteomic characterization of classical and non-classical monocyte subsets
Monocytes are bone marrow-derived leukocytes that are part of the innate immune
system. Monocytes are divided into three subsets: classical, intermediate and non-classical,
which can be differentiated by their expression of some surface antigens, mainly CD14 and CD16.
These cells are key players in the inflammation process underlying the mechanism of many
diseases. Thus, the molecular characterization of these cells may provide very useful information
for understanding their biology in health and disease. We performed a multicentric proteomic
study with pure classical and non-classical populations derived from 12 healthy donors. The robust
workflow used provided reproducible results among the five participating laboratories. Over 5000
proteins were identified, and about half of them were quantified using a spectral counting approach.
The results represent the protein abundance catalogue of pure classical and enriched non-classical
blood peripheral monocytes, and could serve as a reference dataset of the healthy population.
The functional analysis of the differences between cell subsets supports the consensus roles assigned
to human monocytes
In-depth proteomic characterization of classical and non-classical monocyte subsets
Monocytes are bone marrow-derived leukocytes that are part of the innate immune
system. Monocytes are divided into three subsets: classical, intermediate and non-classical,
which can be differentiated by their expression of some surface antigens, mainly CD14 and CD16.
These cells are key players in the inflammation process underlying the mechanism of many
diseases. Thus, the molecular characterization of these cells may provide very useful information
for understanding their biology in health and disease. We performed a multicentric proteomic
study with pure classical and non-classical populations derived from 12 healthy donors. The robust
workflow used provided reproducible results among the five participating laboratories. Over 5000
proteins were identified, and about half of them were quantified using a spectral counting approach.
The results represent the protein abundance catalogue of pure classical and enriched non-classical
blood peripheral monocytes, and could serve as a reference dataset of the healthy population.
The functional analysis of the differences between cell subsets supports the consensus roles assigned
to human monocytes
Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
Whether people living with HIV who have not received antiretroviral therapy (ART) and have high CD4 cell counts have higher mortality than the general population is unknown. We aimed to examine this by analysis of pooled data from industrialised countries
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
Background: There is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis. Methods: We identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, hadCD4+ cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4+ cell count and HIV-RNA via inverse probability weighting. Results: Out of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis. Conclusion: With the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries